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osting by EAbstract Mycosis fungoides is the most common type of Cutaneous T-cell Lymphoma. Data on
clinical characteristics and disease progression in children with mycosis fungoides are limited. Five
patients from the Middle East with childhood mycosis fungoides are reported here. Four of those
patients presented with hypopigmented patches as the sole manifestation of the disease. Histopath-
ologic features were consistent with mycosis fungoides in all patients and in four of ﬁve patients
CD4+ phenotype was over-represented immunohistochemically. All patients had excellent progno-
sis. Only one patient with the classic erythematous patch/plaque type progressed to stage IIA. It
seems the phenotype expression with either CD4+ or CD8+ has no implication on disease pro-
gression. However, the clinical morphologic type might impact disease progression with the hypo-
pigmented type being the variant with the best prognosis. Further studies with large number of
patients are required for better characterization of Middle Eastern patients with childhood MF.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Mycosis fungoides (MF) is the most common form of Cutane-
ous T-cell Lymphoma (CTCL). It is primarily a disease of old-
er patients where approximately 75% of patients are diagnosed
after the age of 50 years (Weinstock and Horm, 1988). Only4691432.
.sa
y. Production and hosting by
Saud University.
lsevier0.5–5% of all cases are diagnosed before the age of 20 years
(Peters et al., 1990). Unusual variants of MF have been de-
scribed including purpuric, follicular, bullous, verrucous,
hyperpigmented, and hypopigmented (Cerroni et al., 1998).
The diagnosis of early MF is often delayed because the long-
standing patches may resemble inﬂammatory dermatoses such
as atopic dermatitis, psoriasis, pityriasis versicolor, or pityriasis
alba that are frequently seen in the pediatric population.
Onset of MF in childhood is rare. In a recent series, 22 pedi-
atric patients with MF were enrolled in an international regis-
try where they present with MF in the ﬁrst decade of life with
early stage disease and unusual forms (Pope et al., 2010). The
clinicopathologic, immunophenotypic, and prognostic features
of MF have not been well deﬁned. We analyzed the clinical,
histopathologic and immunohistochemical ﬁndings and follow
up data in ﬁve Middle Eastern children in whom MF had been
histologically diagnosed before the age of 14 years.
Figure 3 Histologic specimen from a hypopigmented lesion
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Five Saudi male children (Fitzpatrick skin types IV–V) pre-
senting with hypopigmented and classic patch/plaque lesions
of MF were reported in this study. The mean age at diagnosis
was 9 years (range: 6–13 years). All children were seen and
evaluated through the out-patient clinic in the Department
of Dermatology at King Saud University. Four patients pre-
sented with hypopigmented patches as the sole manifestation
of the disease (Figs. 1 and 2) and one patient presented with
erythematous classic patch/plaque presentation. No patient
had signs of atopic dermatitis, psoriasis, or other inﬂammatory
skin diseases. Clinical data of all patients are summarized in
Table 1.Figure 1 Multiple hypopigmented patches of MF on the
anterior trunk.
Figure 2 Multiple hypopigmented lesions on right leg.
Hypopigmented variant of MF.
Table 1 Clinical data of patients with childhood MF.
Patient
No.
Sex Age at
diagnosis
(year)
Age at
onset
(year)
Morphology
at diagnosis
Stage at
diagnosis
Hist
char
1 M 7 5 Hypopigmented IA MF
2 M 6 r Hypopigmented IA MF
3 M 13 7 Hypopigmented IA MF
4 M 6 4 Classic patch/plaque IIA MF
5 M 13 12 Hypopigmented IA MF
CD4, T-helper lymphocytes; CD8, T-cytotoxic lymphocytes; MF, mycos
showing epidermotropic atypical lymphocytes. (Hematoxylin-
eosin stain; original magniﬁcation: ·400)In all cases, one or more biopsy specimens were obtained for
histopathologic examination. Diagnosis was based on the clini-
cal features combined with the histopathologic ﬁndings of MF.
The slides were reviewed by two dermatopathologists. Each
biopsy was subjected to immunohistochemical studies using
monoclonal antibodies CD3, CD4, and CD8. The evaluation
of each child included a detailed personal and family history,
physical examination, routine laboratory tests, peripheral blood
smear, chest X-ray, and abdominal ultrasound. Lymph node
biopsy was performed when there was palpable lymphadenopa-
thy. Staging was done according to the TNM staging system.
3. Results
The clinical data of the patients are presented in Table 1. All pa-
tients were in good health andwithout a remarkablemedical his-
tory. All patients had early MF. Four presented as pure
hypopigmented patches and one patient presented with ery-
thematous patches and plaques. Histopathologic features were
consistent with MF in all cases (Fig. 3). Immunohistochemical
studies revealed predominance of CD4+ phenotype in four
patients while in one patient CD8+ was the predominant phe-
notype (Figs. 4 and 5). All patients had stage IA disease except
the patient with classic erythematous patch/plaque presentation
who progressed from stage 1A to stage IIA. All patients were
treated with topical corticosteroids or NB-UVB with complete
or almost complete response. Results are summarized in
Table 1.ologic
acteristic
Predominant
phenotype
Follow-up
up to present (year)
CD4+ Alive, stable disease
CD8+ Alive, complete remission
CD4+ Alive, stable disease
CD4+ Alive, initially progressive then stable disease
CD4+ Alive, stable disease
is fungoides.
Figure 4 Immunohistochemical features (original magniﬁcation
·400)-note the presence of CD4+ epidermal lymphocytes for
patient number 2.
Figure 5 Immunohistochemical features (original magniﬁcation
·400)-note the predominance of CD8+ epidermal lymphocyte for
the same patient (number 2). The only patient with predominance
of CD8+ phenotype.
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MF is the most common primary skin T-cell Lymphoma in
adults. Recently the reports of childhood MF are accumulat-
ing and increasing. However, true incidence in pediatric age
and characterization of clinical symptoms, histochemical and
immunophenotypic ﬁndings are still to be determined. Re-
ported incidence of MF is 0.5 per 100,000 per year. Approxi-
mately 75% of patients are diagnosed after the age of
40 years (Weinstock and Horm, 1988), whereas only 0.5–5%
of all cases are diagnosed before the age of 20 years (Peters
et al., 1990). Ardigo et al. (2003) address that 17 of 96 patients
of MF reported in the literature for whom complete documen-
tation was available were children (17.7%), a high percentage
given the rarity of the disease in this age group.
Several unusual variants of MF have been reported in chil-
dren. The hypopigmented variant of MF is known to have a
particular propensity for young patients (Zackheim et al.,
1996; Lambroza et al., 1995) and is found almost exclusively
in individuals with black or dark skin (Lambroza et al.,
1995; Garzon, 1999). It has been reported in 20.4% of all pedi-
atric patients with MF. Usually it presents without pruritus
and in combination with classic lesions of MF (Garzon,1999). Macular hypopigmentation as the sole manifestation
of MF in childhood has been reported in only a few cases
(Lambroza et al., 1995; Neuhaus et al., 2000). In this series
four patients presented with hypopigmented macules and
patches as the sole manifestation of the disease. Ardigo et al.
(2003) report that the presence of a mixed clinical pattern of
hypopigmented and erythematous is predominantly observed
in Caucasian patients; on the other hand, subtle erythematous
lesions may be difﬁcult to identify in dark-skinned individuals.
Histopathologic ﬁndings in our patients were all consistent
with MF. Immunohistochemical studies in four of the ﬁve de-
scribed cases revealed that the epidermotropic cells were pre-
dominantly CD4+ and only one case was expressing
CD8+. Among all cases presenting with hypopigmentation
only one case was predominantly CD8+. The single case in
our series that presented with the classic erythematous patch/
plaque MF was predominantly CD4+. The fact that most
of our cases presented with hypopigmented patches are
CD4+ is not in concordance with previous reports. Moreover,
80% of patients presented in the current paper are predomi-
nantly CD4+ is not also in full agreement with what have
been described in the literature. El Shabrawi-Caelen et al.
(2002), described the prevalence of CD8+ lymphocytes in
the epidermal inﬁltrate as typical of hypopigmented MF.
Other reports also concluded that CD8+ MF is over-repre-
sented in the pediatric age group (Ardigo et al., 2003; Zack-
heim et al., 1996; Wain et al., 2003).
T-Cell Receptor (TCR)-gene rearrangement analysis is not
performed routinely in our institution. Therefore, none of our
patients underwent this study. However, it should be remem-
bered that although monoclonality has been detected in the
majority of hypopigmented MF lesions, several studies have
reported the cases of hypopigmented MF with negative
TCR-gene rearrangement (Neuhaus et al., 2000; Di et al.,
1997). Furthermore, monoclonality is not synonymous with
malignancy. Many benign dermatoses including inﬂammatory
stages of vitiligo can harbor monoclonal T-cell populations
(Cribier et al., 2000).
The differentiation between hypopigmented MF and early
stage inﬂammatory vitiligo was an area of signiﬁcant discus-
sion in the literature. In a recent report, Gomez-Moyano
et al. (2010) stated that confusion with vitiligo extends to in-
volve the microscopic diagnosis as both can show similar his-
topathologic features. The histopathologic features of vitiligo
(especially when biopsies are taken from the periphery of the
depigmented lesions) may show striking similarity to hypopig-
mented MF and they conclude that hypopigmented lesions
characterized by CD8+ phenotype and a decrease in melano-
cytes must be evaluated carefully. El-Darouti et al. (2006) in
their work in differentiating hypopigmented MF from vitiligo
described that monoclonality alone is not always enough to
differentiate between the two diseases. Furthermore, immuno-
histochemical analysis of both vitiligo and hypopigmented MF
samples for CD3, CD4, and CD8 showed no signiﬁcant differ-
ence between both groups statistically. They stressed that it is
possible to differentiate between the two conditions by relying
on the histopathologic clues. Epidermotropism, hydropic
degeneration of basal cells, partial loss of pigment, preserva-
tion of at least some of the melanocytes, presence of lympho-
cytes within the papillary dermis, increased density of the
dermal inﬁltrate and wiry ﬁbrosis of the papillary dermal col-
lagen were detected with a signiﬁcantly higher incidence in
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the basement membrane, complete loss of pigmentation, total
absence of melanocytes, as well as, absence or sparseness of
melanocytes in the dermal papillae were seen much more fre-
quently in vitiligo with statistical signiﬁcance. In our series
all hypopigmented MF patients presented with sole manifesta-
tion of hypopigmentation with no erythematous borders and
most of them express CD4+ phenotype. Moreover, vitiligo
is very common in our region and most patients develop with
time typical depigmented macules and patches. None of our
patients here progressed to depigmented stage including those
with the longest follow up.
All patients reported here with childhood MF had a benign
course with excellent prognosis so far. Follow up period of our
patients up to the date of submission of this report ranged
from 2 to 9 years. None developed any serious complication
or worsening of disease course. The longest follow up was
9 years (patient number 2) that present with hypopigmentation
and CD8+ phenotype expression. The only patient (patient
number 4) who progressed to stage IIA was of the erythema-
tous classic patch/plaque type with overpresentation of
CD4+. The patient progressed initially to stage IIA but then
to follow a stable course for more than 2 years and up to the
date of this report. It seems the phenotype expression either
with CD4+ or CD8+ has no implication on disease progres-
sion or prognosis, However, the clinical morphologic type of
MF might impact disease progression with hypopigmented
variant being the type with the best favorable prognosis. Wain
et al. (2003) conclude that hypopigmented variant of juvenile
MF appears to confer a better prognosis than classical MF
and a cytotoxic immunophenotype is also more common
among juvenile-onset patients and is not associated with a
worse prognosis.
In conclusion, this report of childhood MF from the Mid-
dle East showed that hypopigmented variant is the most preva-
lent presentation in our area. Typically the hypopigmented
patches present as the sole cutaneous manifestation with no
associated erythematous patches or plaques with CD4+ phe-
notype being the most over-represented immunohistochemi-
cally. The disease carries excellent prognosis particularly with
the hypopigmented variant. However, studies with large num-
ber of patients are required for better characterization of Mid-
dle Eastern patients with childhood MF.References
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